Brind.

Precigen, Inc. received non-dilutive financing from Pharmakon Advisors, LP for its novel immunotherapy candidate, PAPZIMEOS.

2 reports, 2 independent Updated Sep 3
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
3
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Precigen, Inc. received non-dilutive financing from Pharmakon Advisors, LP for its novel immunotherapy candidate, PAPZIMEOS.

Who's involved

What this event is mainly about
Precigen, Inc

How it developed

Newest first. Tap a step to see who reported it.
  1. The FDA granted approval for Papzimeos, a drug developed by Precigen, Inc.Sub-event
  2. Precigen secured financing from Pharmakon Advisors for its immunotherapy candidate PAPZIMEOS.1 source
  3. FDA approved PAPZIMEOS therapy from Precigen, Inc., a major milestone for the drug.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • PR NewswirePrecigen Announces Up to $125 Million Non-Dilutive Financing $100 million funded at close fortifies balance sheet and supports robust US commercialization of PAPZIMEOS, as well as potential expansion
  • Simply Wall St.Precigen (PGEN) Is Up 32.3% After FDA Approval of First Therapy for Recurrent Respiratory Papillomatosis Earlier this month, Precigen announced that the US Food and Drug Administration (FDA) granted